GREENLAND MINES LTD Stock-Based Compensation
GREENLAND MINES LTD (GRML) reported Stock-Based Compensation of $5.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-17
- GREENLAND MINES LTD share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $111.08K, a 71.53% decline year-over-year.
- GREENLAND MINES LTD share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $5.11M, a 930.76% increase year-over-year.
- GREENLAND MINES LTD share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $39.93K, a 93.94% decline year-over-year.
- GREENLAND MINES LTD share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $639.59K, a 67.25% decline year-over-year.
- GREENLAND MINES LTD share-based payment arrangement, noncash expense for fiscal 2025 was $1.57M, a 40.93% decline from fiscal 2024.
- GREENLAND MINES LTD share-based payment arrangement, noncash expense for fiscal 2024 was $2.65M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $111.08K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | $5.22M 10-Q · filed 2026-08-17 | $5.26M derived: sum of 3 quarters · filed 2026-08-17 | $5.90M derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $5.11M 10-Q/A · filed 2026-08-14 | $5.15M derived: sum of 2 quarters · filed 2026-08-14 | $5.79M derived: sum of 3 quarters · filed 2026-08-14 | $6.18M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $39.93K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $679.52K derived: sum of 2 quarters · filed 2026-08-14 | $1.07M derived: sum of 3 quarters · filed 2026-08-14 | $1.57M 10-K/A · filed 2026-08-14 |
| 2025-09-30 | $639.59K 10-Q · filed 2025-11-13 | $1.03M derived: sum of 2 quarters · filed 2025-11-13 | $1.53M 10-Q · filed 2025-11-13 | $2.18M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $390.19K 10-Q · filed 2025-08-18 | $885.70K 10-Q · filed 2026-08-17 | $1.54M derived: sum of 3 quarters · filed 2026-08-14 | $3.50M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $495.50K 10-Q/A · filed 2026-08-14 | $1.15M derived: sum of 2 quarters · filed 2026-08-14 | $3.11M derived: sum of 3 quarters · filed 2026-08-14 | $3.15M derived: sum of 4 quarters · filed 2026-08-14 |
| 2024-12-31 | $659.21K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $2.61M derived: sum of 2 quarters · filed 2026-08-14 | $2.65M derived: sum of 3 quarters · filed 2026-08-14 | $2.65M 10-K/A · filed 2026-08-14 |
| 2024-09-30 | $1.95M 10-Q · filed 2025-11-13 | $1.99M derived: sum of 2 quarters · filed 2025-11-13 | $1.99M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $37.51K 10-Q · filed 2025-08-18 | $37.51K 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | $287.25K 10-Q · filed 2025-05-15 | |||
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |